Idorsia’s daridorexant delivers outstanding results in a Phase 2 study in children with insomnia disorder
· idorsia pharmaceuticals ltd
AI Briefing
- Idorsia's daridorexant shows promise in treating insomnia disorder in children
- Positive results in a Phase 2 study
- Daridorexant may offer new hope for treatment of insomnia in pediatric population
Advertisement